A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents
2008

A New Model for Studying HER2/neu Breast Cancer

publication Evidence: moderate

Author Information

Author(s): Marie P. Piechocki

Primary Institution: Wayne State University and Karmanos Cancer Center

Hypothesis

The study aims to evaluate the effects of therapeutic agents on the tumor microenvironment in invasive cancers using a co-culture model.

Conclusion

The MAM-1 model demonstrates the specificity of Iressa for HER2/neu expressing tumor cells and highlights the differential responses of tumor and stromal cells to treatment.

Supporting Evidence

  • The MAM-1 model maintains a 1:1 ratio of tumor to stromal cells for over 20 passages.
  • Iressa treatment resulted in a selective reduction of tumor cell markers while increasing stromal cell markers.
  • Flow cytometric analysis showed distinct populations of tumor and stromal cells in the co-culture.

Takeaway

Researchers created a special lab model to study how a cancer drug affects breast cancer cells and their surrounding support cells, finding that the drug works better on the cancer cells than on the support cells.

Methodology

The study used a co-culture model of HER2/neu positive tumor cells and alpha-SMA expressing stromal cells, characterized by microarray analysis and flow cytometry.

Limitations

The model may not fully replicate the complexity of in vivo tumor microenvironments.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-8-119

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication